Pembrolizumab for Early Triple-Negative Breast Cancer

New England Journal of Medicine, Journal Year: 2020, Volume and Issue: 382(9), P. 810 - 821

Published: Feb. 26, 2020

Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients early triple-negative breast cancer. Whether the addition of to neoadjuvant chemotherapy would significantly increase percentage cancer who have a pathological complete response (defined as no invasive negative nodes) at definitive surgery is unclear.

Language: Английский

---

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 384(25), P. 2394 - 2405

Published: June 3, 2021

Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.

Language: Английский

---

Breast cancer

The Lancet, Journal Year: 2021, Volume and Issue: 397(10286), P. 1750 - 1769

Published: April 2, 2021

Language: Английский

---

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

The Lancet, Journal Year: 2020, Volume and Issue: 396(10257), P. 1090 - 1100

Published: Sept. 20, 2020

Language: Английский

---

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Annals of Oncology, Journal Year: 2021, Volume and Issue: 32(10), P. 1216 - 1235

Published: July 6, 2021

Language: Английский

---

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(6), P. 556 - 567

Published: Feb. 9, 2022

The addition of pembrolizumab to neoadjuvant chemotherapy led a significantly higher percentage patients with early triple-negative breast cancer having pathological complete response (defined as no invasive in the and negative nodes) at definitive surgery an earlier analysis this phase 3 trial adjuvant therapy. primary results regarding event-free survival have not been reported.

Language: Английский

---

Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)

Cancers, Journal Year: 2022, Volume and Issue: 14(10), P. 2569 - 2569

Published: May 23, 2022

Breast cancer is the most-commonly diagnosed malignant tumor in women world, as well first cause of death from tumors. The incidence breast constantly increasing all regions world. For this reason, despite progress its detection and treatment, which translates into improved mortality rates, it seems necessary to look for new therapeutic methods, predictive prognostic factors. Treatment strategies vary depending on molecular subtype. treatment multidisciplinary; includes approaches locoregional therapy (surgery radiation therapy) systemic therapy. Systemic therapies include hormone hormone-positive disease, chemotherapy, anti-HER2 HER2-positive quite recently, immunotherapy. Triple negative responsible more than 15–20% cancers. It particular research interest presents a challenge, mainly due low response highly invasive nature. Future concepts aim individualize de-escalate escalate based biology early article review literature carcinoma—a disease affecting

Language: Английский

---

Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality

Cancer Treatment Reviews, Journal Year: 2022, Volume and Issue: 105, P. 102375 - 102375

Published: March 4, 2022

Adjuvant and neoadjuvant breast cancer treatments can reduce mortality but may increase from other causes. Information regarding treatment benefits risks is scattered widely through the literature. To inform clinical practice we collated reviewed highest quality evidence.Guidelines were searched to identify adjuvant or options recommended in early invasive cancer. For each option, systematic literature searches identified highest-ranking evidence. radiotherapy risks, for dose-response relationships modern organ doses also undertaken.Treatment USA elsewhere included chemotherapy (anthracycline, taxane, platinum, capecitabine), anti-human epidermal growth factor 2 therapy (trastuzumab, pertuzumab, trastuzumab emtansine, neratinib), endocrine (tamoxifen, aromatase inhibitor, ovarian ablation/suppression) bisphosphonates. Radiotherapy after conserving surgery (whole breast, partial tumour bed boost, regional nodes) mastectomy (chest wall, nodes). Treatment supported by randomised evidence, including > 10,000 women eight comparisons, 1,000-10,000 fifteen < 1,000 one. Most comparisons reduced recurrence 10-25%, with no non-breast-cancer death. Anthracycline increased overall mortality. risk was heart disease leukaemia. Radiation-risks mainly disease, lung oesophageal cancer, increasing heart, oesophagus radiation respectively. Taxanes leukaemia risk.These decisions individuals recommendations groups of women.

Language: Английский

---

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Annals of Oncology, Journal Year: 2019, Volume and Issue: 30(11), P. 1784 - 1795

Published: Aug. 29, 2019

Language: Английский

---

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications

Cells, Journal Year: 2021, Volume and Issue: 10(2), P. 223 - 223

Published: Jan. 23, 2021

In recent decades, the increasing interest in field of immunotherapy has fostered an intense investigation breast cancer (BC) immune microenvironment. this context, tumor-infiltrating lymphocytes (TILs) have emerged as a clinically relevant and highly reproducible biomarker capable affecting BC prognosis response to treatment. Indeed, evaluation TILs on primary tumors proved be strongly prognostic triple-negative (TN) patients treated with either adjuvant or neoadjuvant chemotherapy, well early TNBC not receiving any systemic treatment, thus gaining level-1b evidence setting. addition, strong relationship between pathologic complete after chemotherapy been reported all subtypes role higher HER2-positive also demonstrated. The infiltrates further fueled by introduction first checkpoint inhibitors treatment armamentarium advanced PD-L1-positive status FDA-approved assays. However, despite these advances, reliably exhaustively predicting benefit is still lacking, highlighting imperative need deepen issue. Finally, more comprehensive integrating both quantity quality cells incorporation composite scores encompassing other biologically biomarkers, adoption software-based and/or machine learning platforms for characterization infiltrates, are emerging promising strategies potentially optimizing patient selection stratification research field. present review, we summarize available updates BC, focusing current clinical applications, potential implications major unresolved issues.

Language: Английский

---